Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: positive data in RSV in infants

( - Sanofi reports new positive data from the HARMONIE Phase IIIb clinical trial, confirming that its nirsevimab prevents hospitalisations of infants due to RSV with high and consistent efficacy.

They show an 83.21% reduction in hospitalisations for lower respiratory tract infections in infants under 12 months of age who received a single dose of nirsevimab compared to those who received no preventive treatment.

Over 8,000 infants were included in the study, which took place in France, Germany and the UK. The data was presented at the 41st Annual Congress of the European Society for Paediatric Infectious Diseases (ESPID).

Copyright (c) 2023 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.